• Loading stock data...
Est. 2004

LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More or Call (407) 374-6986

Wednesday 11/14/2018
SMALL CAP MARKET NEWS

We release small market news updates daily, 5 times a week! Always check back to get the inside scoop on what going on.


LEVERAGE OUR MASSIVE INVESTOR AUDIENCE!

Stock Investors · Accredited Investors · Hedge Fund Investors

Learn More

vaccine

  • 3:42 PM

    Research Article Describes Inadequate Funding Levels for Vaccines Against HIV, Malaria and Tuberculosis ATLANTA, GA, Sept. 19, 2018 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, today commented on a research article describing a study funded by the Gates Foundation.  In the article, “Developing new health technologies for neglected diseases: a pipeline portfolio review and cost model”, published at Gates Open Research1, the authors discussed their review of product development pipelines for 35

    Read more
  • 1:25 PM

    ATLANTA, GA, , May 24, 2018 (GLOBE NEWSWIRE) — GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded the Company a Small Business Innovative Research (SBIR) grant in support of its novel Zika vaccine development program. The grant award of $300,000 will fund the second year of a two-year project period with a total budget of $600,000.

    Read more
  • 3:01 PM

    Supports Production of the DNA Component of GeoVax’s GOVX-B11 Preventive HIV Vaccine ATLANTA, GA–GOVX, (Marketwired – Aug 2, 2016) – GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing human vaccines, announced today that the National Institute of Allergy and Infectious Diseases, (NIAID) part of the National Institutes of Health (NIH) has awarded it a Staged Vaccine Development contract to further develop GeoVax’s preventive HIV vaccine (GOVX-B11) and to manufacture the DNA component of GOVX-B11 for use in advanced human

    Read more
  • 3:31 PM

    LITTLE RIVER, S.C., Jan. 26, 2016, IEVM, /PRNewswire/ — Integrated Environmental Technologies, Ltd. (OTCQB: IEVM) today announced that as of December 31, 2015, the Company had provided Excelyte® well maintenance treatments on 235 wells, an increase of 200 wells, or 571%, since December 31, 2014.  The Company performed 1,447 Excelyte® well maintenance treatments during the year ended December 31, 2015, generating $458,000 in revenue, an increase of $399,000, or 677%, from the amount of revenue generated during the year endedDecember 31,

    Read more
  • 3:17 PM

    LITTLE RIVER, S.C., Sept. 29, 2014 /PRNewswire via COMTEX/ — Integrated Environmental Technologies, Ltd. (OTCBB: IEVM) today announced that it has commenced well maintenance treatments utilizing its flagship product Excelyte(TM) on five additional oil producing wells for an existing customer, and now is treating an aggregate of eleven wells for this customer. The company is in the process of scheduling well maintenance treatments for additional oil producing wells operated by this customer in the Uinta Basin with the goal of treating

    Read more
  • 1:46 PM

    LITTLE RIVER, Jul 25, 2014 (GLOBE NEWSWIRE via COMTEX) — Integrated Environmental Technologies, Ltd. (OTCBB:IEVM) today announced that it has increased the use of its flagship Excelyte(TM) product in the Uinta Basin in Utah. The company added a new customer with significant oil producing operations in the Uinta Basin and successfully completed the initial treatment on six of the customer’s oil producing wells, reducing the amount of hydrogen sulfide in each of the oil wells treated with Excelyte. The company

    Read more
Public Wire Banner